Last reviewed · How we verify
HTL0039732 Capsules and atezolizumab infusion
HTL0039732 Capsules and atezolizumab infusion is a Small molecule drug developed by Cancer Research UK. It is currently in Phase 1 development.
At a glance
| Generic name | HTL0039732 Capsules and atezolizumab infusion |
|---|---|
| Sponsor | Cancer Research UK |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HTL0039732 in Participants With Advanced Solid Tumours (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HTL0039732 Capsules and atezolizumab infusion CI brief — competitive landscape report
- HTL0039732 Capsules and atezolizumab infusion updates RSS · CI watch RSS
- Cancer Research UK portfolio CI
Frequently asked questions about HTL0039732 Capsules and atezolizumab infusion
What is HTL0039732 Capsules and atezolizumab infusion?
HTL0039732 Capsules and atezolizumab infusion is a Small molecule drug developed by Cancer Research UK.
Who makes HTL0039732 Capsules and atezolizumab infusion?
HTL0039732 Capsules and atezolizumab infusion is developed by Cancer Research UK (see full Cancer Research UK pipeline at /company/cancer-research-uk).
What development phase is HTL0039732 Capsules and atezolizumab infusion in?
HTL0039732 Capsules and atezolizumab infusion is in Phase 1.